









Markets
/
Stocks
/
nasdaq-rlyb
/

Rallybio Corp

RLYB

0.589USD

-0.011-1.77%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

24.55MMarket Cap

LossP/E TTM



Rallybio Corp

0.589

-0.011-1.77%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite an average stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

161 / 506

Overall Ranking

272 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Hold

Current Rating

1.000

Target Price

+66.89%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical needs in the areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. It has two clinical-stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Its other product candidates include RLYB114, RLYB331 and ENPP1 Program. Its second C5 inhibitor, RLYB114, is a pegylated C5-targeted Affibody molecule with PK properties designed for the treatment of complement-mediated ophthalmic diseases. RLYB331 is for the treatment of severe anemia.

Growing

The company is in a growing phase, with the latest annual income totaling USD 636.00K.

Overvalued

The company’s latest PE is -0.64, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 33.40M shares, decreasing 13.51% quarter-over-quarter.

Held by Andreas Halvorsen

Star Investor Andreas Halvorsen holds 4.19M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.43.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 7.39, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 212.00K, representing a year-over-year decrease of 29.10%, while its net profit experienced a year-over-year decrease of 40.24%.

Score

Industry at a Glance

Previous score

7.39

Change



Financials

8.43

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.94

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

3.06

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.55

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -0.65, which is 1.90% below the recent high of -0.66 and -272.57% above the recent low of -2.42.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 161/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 6.50, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Rallybio Corp is 1.00, with a high of 1.00 and a low of 1.00.

Score

Industry at a Glance

Previous score

6.50

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Hold

Current Rating

1.000

Target Price

+66.89%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Rallybio Corp

RLYB

CRISPR Therapeutics AG

CRSP

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 4.37, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 0.67 and the support level at 0.51, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.37

Change

-0.05

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.009

Neutral

RSI(14)

53.183

Neutral

STOCH(KDJ)(9,3,3)

38.643

Neutral

ATR(14)

0.037

Low Volatility

CCI(14)

52.272

Neutral

Williams %R

29.487

Buy

TRIX(12,20)

0.349

Sell

StochRSI(14)

50.646

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

0.590

Sell

MA10

0.592

Sell

MA20

0.587

Buy

MA50

0.540

Buy

MA100

0.438

Buy

MA200

0.596

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 80.25%, representing a quarter-over-quarter decrease of 2.15%. The largest institutional shareholder is Andreas Halvorsen, holding a total of 4.19M shares, representing 10.04% of shares outstanding, with 0.66% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Viking Global Investors LP

Star Investors

4.19M

Johnson & Johnson Innovation-JJDC, Inc.

3.64M

5AM Ventures

3.63M

New Leaf Venture Partners LLC

3.30M

TPG Capital, L.P.

3.03M

Pivotal Bioventure Partners Investment Advisor LLC

2.40M

Fidelity Management & Research Company LLC

1.79M

+1.05%

Almitas Capital LLC

1.30M

+0.19%

abrdn Inc.

1.73M

Canaan Partners

1.53M

-9.73%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.03, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is -1.08. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.